0000000000115300

AUTHOR

Gemma Bruera

showing 7 related works from this author

TRIPLET SCHEDULE OF WEEKLY 5-FLUOROURACIL AND ALTERNATING IRINOTECAN OR OXALIPLATIN IN ADVANCED COLORECTAL CANCER: A DOSE-FINDING AND PHASE II STUDY.

2010

A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose- finding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsMaximum Tolerated DoseOrganoplatinum CompoundsSettore MED/06 - Oncologia Medica5-FluorouracilPhases of clinical researchIrinotecanGastroenterologyInternal medicineCPT-11Antineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdvanced colorectal cancerAgedDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseOxaliplatinIrinotecanOxaliplatinSurvival RateRegimenTreatment OutcomeOncologyTolerabilityFluorouracilLymphatic MetastasisToxicityl-OHPCamptothecinFemaleFluorouracilbusinessColorectal NeoplasmsFebrile neutropeniamedicine.drug
researchProduct

The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevac…

2015

Bevacizumab-containing chemotherapy differently predict increased efficacy in KRAS exon 2 mutant and wild-type metastatic colorectal cancer (MCRC) patients. Mutant compared to wild-type status did not significantly affect progression-free survival (PFS) and overall survival (OS) in patients fit for first line bevacizumab-containing FIr-B/FOx regimen, and after progression. In patients unfit for intensive regimens, mutant status significantly affected PFS, while not OS. Codon 12 KRAS mutations differentially affect GTPase function, and confer worse clinical behaviour. Prognostic relevance of the prevalent c.35 G. >. A KRAS mutation was retrospectively evaluated. Fit c.35 G. >. A mutant patie…

OncologyVascular Endothelial Growth Factor APathologyKRAS c.35 G>A mutationColorectal cancermedicine.medical_treatmentMutantIntensive regimenColorectal Neoplasmmedicine.disease_causeExonMutation RateAntineoplastic Combined Chemotherapy ProtocolsNeoplasm MetastasisProto-Oncogene ProteinMetastatic colorectal cancerHematologyExonsPrognosisNeoplasm MetastasiBevacizumabTreatment OutcomeOncologyDisease ProgressionBiomarker (medicine)KRASColorectal NeoplasmsHumanmedicine.drugmedicine.medical_specialtyBevacizumabGenotypePrognosiExonAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsmedicineHumansChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryBiomarkerras Proteinmedicine.diseaseRegimenMutationras ProteinsBevacizumab; Biomarker; Intensive regimens; KRAS c.35 G>A mutation; Metastatic colorectal cancer; Antibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Colorectal Neoplasms; Disease Progression; Genotype; Humans; Mutation Rate; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Vascular Endothelial Growth Factor A; ras Proteins; Exons; Mutation; Hematology; Oncology; Geriatrics and GerontologyGeriatrics and GerontologybusinessBiomarkers
researchProduct

Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic th…

2017

// Gemma Bruera 1, 2 , Antonio Russo 3 , Antonio Galvano 3 , Sergio Rizzo 3 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy Correspondence to: Antonio Russo, email: antonio.russo@usa.net Keywords: elderly, intensive treatment, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, unfit Received: June 07, 2016     Accepted: November 24, 2016     Published:…

Male0301 basic medicineUnfitmedicine.medical_specialtyBevacizumabColorectal cancerDecision MakingAngiogenesis InhibitorsNeutropeniamedicine.disease_cause03 medical and health sciences0302 clinical medicineElderlyInternal medicinemedicineMucositisHumansNeoplasm MetastasisAgedRetrospective StudiesTriplet chemotherapy plus bevacizumabbusiness.industryMetastatic colorectal cancerelderly; intensive treatment; metastatic colorectal cancer; triplet chemotherapy plus bevacizumab; unfitRetrospective cohort studymedicine.diseaseComorbiditySurgeryRegimenTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleIntensive treatmentKRASClinical Research PaperColorectal NeoplasmsbusinessElderly; Intensive treatment; Metastatic colorectal cancer; Triplet chemotherapy plus bevacizumab; Unfit; Oncologymedicine.drug
researchProduct

Dose-finding study of oxaliplatin associated to capecitabinebased preoperative chemoradiotherapy in locally advanced rectal cancer

2018

// Gemma Bruera 1, 2 , Mario Di Staso 3 , Pierluigi Bonfili 3 , Antonio Galvano 4 , Rosa Manetta 5 , Gino Coletti 6 , Roberto Vicentini 7 , Stefano Guadagni 2, 8 , Corrado Ficorella 2, 9 , Ernesto Di Cesare 2, 3 , Antonio Russo 4 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Radiotherapy, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 4 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo,…

medicine.medical_specialtyCapecitabine; Chemoradiotherapy; Dose-finding; Locally advanced rectal cancer; Oxaliplatin; OncologyColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentRectumchemoradiotherapyCapecitabine03 medical and health sciences0302 clinical medicinelocally advanced rectal cancermedicineMucositisbusiness.industryGeneral surgerycapecitabineoxaliplatinmedicine.diseaseOxaliplatinRadiation therapyRegimenmedicine.anatomical_structureOncology030220 oncology & carcinogenesisdose-findingClinical Research Paperbusiness030217 neurology & neurosurgeryChemoradiotherapymedicine.drug
researchProduct

Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma

2010

hepatocellular carcinoma, haemophilia, treatment

SorafenibOncologymedicine.medical_specialtyhepatocellular carcinoma haemophilia treatmentbusiness.industryHematologyGeneral Medicinemedicine.diseaseHaemophiliaHepatocellular carcinomaInternal medicinemedicinebusinessGenetics (clinical)medicine.drugHaemophilia
researchProduct

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric canc…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Antonio Galvano 4 , Antonella Dal Mas 5 , Stefano Guadagni 6, 2 , Giuseppe Calvisi 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 , on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy 5 Pathology, S. Salva…

0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaDocetaxelNeutropeniametastatic gastric cancerAnd oxaliplatin03 medical and health sciences0302 clinical medicinedocetaxel 5-fluorouracil and oxaliplatinInternal medicinemedicineMucositisdose-finding study5-fluorouracil5-fluorouracil; And oxaliplatin; Docetaxel; Dose-finding study; FD/FOx intensive regimen; First-line triplet chemotherapy; Metastatic gastric cancer; OncologyHypoalbuminemiabusiness.industrymedicine.diseaseOxaliplatinRegimen030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisfirst-line triplet chemotherapyCohortFD/FOx intensive regimenbusinessmedicine.drugResearch PaperOncotarget
researchProduct

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Stefania Candria 1 , Antonio Galvano 4 , Rosa Manetta 5 , Aldo Victor Giordano 5 , Sergio Carducci 5 , Alessandra Di Sibio 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 and on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, Univers…

0301 basic medicinemedicine.medical_specialtyFOLFIRINOXPhase II studyPhases of clinical research03 medical and health sciences0302 clinical medicineFIr/FOxFIr/FOx; First-line; Metastatic pancreatic ductal adenocarcinoma; Phase II study; Triplet chemotherapyInternal medicinemedicineMucositisPerformance statusbusiness.industryFirst-linemedicine.diseaseGemcitabineOxaliplatinIrinotecan030104 developmental biologyMetastatic pancreatic ductal adenocarcinomaOncology030220 oncology & carcinogenesisLiver functionTriplet chemotherapybusinessResearch Papermedicine.drug
researchProduct